Company Summary - Alliance Pharma PLC (LSE:APH)
30.50p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £73.015m
NEW Explore our new and improved report for Alliance Pharma PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Acquisition, marketing and distribution of pharmaceutical products
| Financials - Interim (7/9/2011) | ||
|---|---|---|
| Turnover | £m | 24.39 |
| Pre-tax Profit | £m | 7 |
| EPS | p | 2.21 |
| DPS | p | 0.17 |
| Director | Board Role |
|---|---|
| Michael Gatenby | Chairman |
| John Dawson | Chief Executive |
| Richard Wright | Finance Director |
| Tony Booley | Sales/Mkt Director |
Products Brands & Subsidiaries
Products & Brands
Acnisal; Actidose Aqua; Alphaderm; Anapolon; Antidotum Thalli-Heyl; Aquadrate; Atarax; Biorphen; Brofl ex; Buccastem; Cafergot...
Subsidiaries
Alliance Pharmaceuticals Ltd; Unigreg Ltd
Broker Sentiment (5 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Notification of Preliminary Results | 02/02/2012 |
| Pre-Close Trading Update | 16/01/2012 |
| Acquisition of Brands | 19/12/2011 |
For more information
and investor relations, visit the
Alliance Pharma PLC company website: